Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1 2Phase 3 1Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1

Conditions

Sarcoma 76Gastrointestinal Stromal Tumors 36Dendritic Cell Sarcoma, Interdigitating 22Glioblastoma 20Liposarcoma 19Gliosarcoma 19Neoplasms 18Leiomyosarcoma 16Bone Neoplasms 16Rhabdomyosarcoma 15Neoplasm Metastasis 15Lymphoma, Large B-Cell, Diffuse 15Burkitt Lymphoma 15Central Nervous System Neoplasms 14Sarcoma, Synovial 13Recurrence 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Osteosarcoma 13Hemangiosarcoma 12Fibrosarcoma 12Multiple Myeloma 11Lymphoma, Non-Hodgkin 11Lymphoma, Mantle-Cell 11Lymphoma, Large-Cell, Immunoblastic 11Lymphoma, Follicular 11Lymphoma, B-Cell, Marginal Zone 11Lymphoma 11Leukemia, Myeloid, Chronic-Phase 11Leukemia, Myeloid, Acute 11Leukemia, Myeloid, Accelerated Phase 11

Interventions

Sorafenib 1Mitoxantrone 1Leyk 1Etoposide 1Daunorubicin 1Cytarabine 1Bortezomib 1Asparaginase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Sarcoma, Myeloid × Sarcoma × Clear all
NCT01371981 2025-11-26

Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
1,645 enrolled 32 charts
Other hematologic neoplasmSarcoma

Leukemia, Myeloid, Acute, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡